Skip to main content
SpringerLink
Log in

Counting hospitalisation costs of cardiac amyloidosis in the US

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. The study was funded by Prothena Biosciences Inc.

Reference

  • Quock TP, et al. Untangling the clinical and economic burden of hospitalization for cardiac amyloidosis in the United States. ClinicoEconomics and Outcomes Research : 15 Jul 2019. Available from: URL: https://doi.org/10.2147/CEOR.S207127

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Counting hospitalisation costs of cardiac amyloidosis in the US. PharmacoEcon Outcomes News 833, 14 (2019). https://doi.org/10.1007/s40274-019-6078-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-019-6078-0

Search

Navigation